CRISPR Therapeutics CRSP Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's additional paid-in capital?
- CRISPR Therapeutics (CRSP) reported additional paid-in capital of $3.88B in Q1 2026.
- How has CRISPR Therapeutics's additional paid-in capital changed year-over-year?
- CRISPR Therapeutics's additional paid-in capital increased by 16.8% year-over-year, from $3.32B to $3.88B.
- What is the long-term trend for CRISPR Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's additional paid-in capital has grown at a 11.6% compound annual growth rate (CAGR), from $2.24B to $3.86B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.